Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol

INTRODUCTION: Newly diagnosed type 2 diabetes mellitus (T2DM) in patients with coronary artery disease (CAD) more than doubles the risk of death compared with otherwise matched glucose tolerant patients. The biguanide metformin is the drug of choice in treatment of T2DM and has shown to ameliorate c...

Descripción completa

Detalles Bibliográficos
Autores principales: Anholm, Christian, Kumarathurai, Preman, Klit, Malene S, Kristiansen, Ole P, Nielsen, Olav W, Ladelund, Steen, Madsbad, Sten, Sajadieh, Ahmad, Haugaard, Steen B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Research Methods
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401817/
https://www.ncbi.nlm.nih.gov/pubmed/25031198
http://dx.doi.org/10.1136/bmjopen-2014-005942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401817/
https://www.ncbi.nlm.nih.gov/pubmed/25031198
http://dx.doi.org/10.1136/bmjopen-2014-005942

Ejemplares similares